Consensus Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 16:00:02 2024-05-01 EDT			5-day change	1st Jan Change
21.74 ^USD	+2.45%		-4.40%	-20.13%

04-04	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
04-04	Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Beam Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

a87fba82347b924c.j0SQFKucUlt4CEGr-PyTRoA8gArYVj2JT2HCSLw0iPY.6R71TIb6PBkvfSn5trmmM8lM7T-XJ1W-CEyDfOpi35f3MOduzPo9PQI-eQ~b7bb6e10b46f8c3621bf4edef32870d5

Analyst Recommendations on Beam Therapeutics Inc.

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04-04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04-04	MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	02-28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	02-28	MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	02-27	MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	01-29	MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	12-15	MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	12-08	MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	23-10-17	MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating	23-08-09	MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating	23-08-09	MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating	23-05-11	MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating	23-05-11	MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating	23-05-11	MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target	23-03-21	MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating	23-03-01	MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target	23-02-01	MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating	23-01-23	MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61	22-12-20	MT
Citigroup Initiates Beam Therapeutics at Buy Rating With $62 Price Target	22-12-13	MT
Credit Suisse Lowers Beam Therapeutics' Price Target to $53 From $65 to Reflect Delays to BEAM-102, Keeps Neutral Rating	22-11-08	MT
Wedbush Adjusts Beam Therapeutics Price Target to $79 From $100, Maintains Outperform Rating	22-11-07	MT
SVB Leerink Adjusts Price Target on Beam Therapeutics to $81 From $82, Maintains Outperform Rating	22-11-07	MT
SVB Securities Adjusts Beam Therapeutics' Price Target to $113 from $118, Keeps Outperform Rating	22-08-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.74 USD

Average target price

49.54 USD

Spread / Average Target

+127.87%

High Price Target

78 USD

Spread / Highest target

+258.79%

Low Price Target

27 USD

Spread / Lowest Target

+24.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Beam Therapeutics Inc.

Barclays
RBC Capital Markets
Wedbush
JPMorgan Chase
BofA Securities
Jefferies & Co.
Cantor Fitzgerald
Credit Suisse
Citigroup
Bernstein
Wells Fargo Securities
SVB Securities LLC
BMO Capital
Guggenheim
SVB Leerink
Redburn
J.P. Morgan Chase

Ratings for Beam Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar